Overview of neoadjuvant endocrine therapy for receptor positive breast cancer in post menopausal women;Überblick über die neoadjuvante endokrine therapie des rezeptorpositiven mammakarzinoms der postmenopausalen frau

Geburtshilfe und Frauenheilkunde

Volumn 64, Issue 12, 2004, Pages 1290-1298

  Paepke, Stefan ^a,f   Harbeck, M ^a   Jacobs, V R ^a   Schwarz Boeger, U ^a   Pildner Von Steinburg, S ^a   Fischer, T ^a   Diedrich, F ^a   Blohmer, J U ^b   Warm, M ^c   Huober, J ^d   Wolf, C ^e   Eiermann, W ^e   Kiechle, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Frauenklinik Rot Kreuz   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anastrozole; Breast cancer; Breast conserving therapy; Exemestane; Letrozole; Neoadjuvant endocrine therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TOLERABILITY; ELDERLY CARE; FEMALE; HUMAN; IN VIVO STUDY; LIVER PRESERVATION; POSTMENOPAUSE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 19944429721     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830391     Document Type: Review

References (44)

1. Anderson EDC, Forrest AP, Levack P et al. Response to endocrine manipulation and estrogen receptor concentration in large operable primary breast cancer. Br J Cancer 1989; 60: 223-226
2. Bergman L, van Dongen JA, van Ooijen B et al. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treatm 1995; 34: 77-83
3. Boeddinghaus IM, Dowsett M, Smith IE et al. Neoadjuvant Arimidex or Tamoxifen, alone or combined, for breast cancer (IMPACT): PgR-related reductions in proliferation marker Ki67. Proc Am Soc Clin Oncol 2000; 19: 94a (Abs360)
4. Bouchardy CH, Rapiti E, Fioretta G et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. JCO 2003; 21: 3580-3587
5. Chow LWC, Toi M, Takebayashi Y et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: second report. Breast Cancer Res Treatm 2003; 82:101 # 428 (Abstract)
6. Dixon JM, Renshaw L, Bellamy C et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double blind, single center study. Clin Cancer Res 2000; 6: 2229-2235
7. Dowsett M on behalf of the IMPACT trialists. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) with Tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cane Res Treatm 2003; 82: # 1 (Abstract)
8. Eiermann W, Paepke S, Appfelstedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-1532
9. Ellis P, Smith L, Salter I et al. Pre-operative/neoadjuvant chemotherapy for early breast cancer induces apoptosis. Proc Ann Meet Am Soc Clin Oncol 1996; 15: S112
10. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. JCO 2001; 18: 3808-3816
11. Fisher B, Gunduz N, Coyle J et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001
12. Gaskell DJ, Hawkins RA, de Carteret et al. Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg 1992; 79: 1317-1320
13. Gazet LC, Ford HT, Coombes RC et al. Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994; 20: 207-214
14. Geisler J, King N, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cane Res 1998; 4: 2089-2093
15. Geisler J. Arimidex - direkte Wirkung auf Tumoröstrogenspiegel. Akt Onkol 2000; 108: 9-15
16. Geisler J, Detre S, Berntsen H et al. Influence of neoadjuvant Anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001; 7: 1230-1236
17. Goss P, Ingle JN, Marino S et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1482-1496
18. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39: 3861-3865
19. Harper-Wynne C, Nigel PMS, Shenton K et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor yorozole in postmenopausal patients with primary breast cancer. JCO 2002; 20: 1026-1035
20. Jackson J, White S, Dixon M et al. Short- and long-term effects of letrozole on tumor histopathology and immunopathology in patients with breast cancer given neoadjuvant treatment. Breast Cancer Res Treatm 2003; 82:102 # 430 (Abstract)
21. Krainick U, Astner A, Jonat W, Wallwiener D. Phase II study to define safety and efficacy of exemestane as preoperative therapy for post-menopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative GENARI). Breast Cancer Res Treatm 2003; 82: 55 #239 (Abstract)
22. Leal da Silva JM, Cardosa F, Oliveira F et al. Neoadjuvant hormonal therapy in locally advanced breast cancer. Eur J Cancer 1998; 34: S15
23. Lichtenegger W, Hackl W, Hüttner C. Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer. ASCO Am Soc Clin Oncol Symposium 2001; # 1832 Abstract)
24. Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996; 5: 202-208
25. Milla-Santos A, Milla I, Rallo L. Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) pts. Breast Cancer Res Treatm 2001; 69: # 302 (Abstract)
26. Miller WR, Dixon JM. Antiaromatase agents: Preclinical data and neoadjuvant therapy. Clinical Breast Cancer 2000; 1: 9-14
27. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002; 9: 9-15
28. Miller WR, Santen RJ. Aromatase Inhibition and Breast Cancer. New York: Marcel Dekker Inc, 2001: 103-117
29. Minckwitz v. G, Costa S, Raab G et al. Dose dense doxorubicin, docetaxel and granulozyte colony stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase II b study. J Clin Oncol 2001; 19: 3506-3515
30. Mustacchi G, Milani S, Pluchinotta A et al. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G. R. E. T. A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 1994; 14: 2197-2200
31. Paepke S, Bouterfa H, Wallwiener D, the Fem D1 Study Group. A multicenter study of preoperative treatment with Femara (Letrozole) for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast Cancer. Breast Bancer Res Treatm 2001; 69: # 453 (Abstract)
32. Paepke St, Hüttner C, Blohmer JU. Pre-operative endocrine therapy for postmenopausal women with ER and/or PgR positive breast cancer: A pathologic complete response of a locally advanced mamma carcinoma after 8 months of neoadjuvant letrozole therapy, (in progr)
33. Paepke S, Bouterfa H, Wallwiener D. A multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Proc Am Soc Clin Oncol 2003; # 321 (Abstract)
34. Robertson LF, Ellis IO, Elston CW et al. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow up. Eur J Cancer 1992; 582-587
35. Semiglazov VF, Semiglazov W, Ivanov VG et al. Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1 - 4 N0 - 1 - 2 M0). Breast Cancer Res Treatm 2003; 82: # 111 (Abstract)
36. Silliman RA. What constitutes optimal care for older women with breast cancer? JCO 2003; 21: 3554-3556
37. Smith I, Dowsett M on behalf of the IMPACT-Trialists. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen-receptor positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treatm 2003; 82: 6, # 1(Abstract)
38. Smith I, Cataliotti L on behalf of the IMPACT and PROACT trialists. Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women. Eur J Cane 2004; 2: 69, # 47 (Abstract)
39. Sokol L. Our first experience with preoperative treatment of postmenopausal locally advanced breast cancer patients with Letrozole. Proc Am Soc Oncol 2003; # 503 (Abstract)
40. Tubiana-Hulin M, Spyratos F, Becette V et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res Treatm 2003; 82:106, # 443 (Abstract)
41. Van Dalsen AD, De Vries J. Treatment of breast cancer in elderly patients. J Surg Oncol 1995; 60: 80-82
42. Valero V, Hoff PM, Singletary SE et al. Combined modality treatment of locally advanced breast cancer (LABC) in elderly patients (PTS) using tamoxifen (TAM) as primary therapy. Proc Am Soc Clin Oncol 1989; 17: 15
43. Wolf C, Ortmann O, Wallwiener D et al. GENARI - Ein Studienkonzept zur Prüfung von Verträglichkeit, Wirksamkeit und Nutzen einer chemoendokrinen präoperativen Behandlung mit Exemestan. Geburtsh Frauenheilk 2002; 62: 333-338
44. Zaccheo T, di Salle E, Capolongo L, Geroni MC. Antitumor effect of the combined treatment with the aromatase inactivator exemestane and epirubicin in a rat breast model. 6th International Congress on Hormones and Cancer 1999; # 18 (Abstract)